GSK Agrees to $2.2 Billion Settlement Over Zantac Cancer Claims

The settlement resolves 93% of the lawsuits alleging that the heartburn drug Zantac caused cancer, with GSK admitting no liability.

GSK will pay up to $2.2 billion to settle approximately 80,000 U.S. lawsuits related to Zantac, covering 93% of the cases.
The settlements address claims that Zantac's active ingredient, ranitidine, could degrade into a carcinogen known as NDMA.
The agreement includes a $70 million settlement of a whistleblower complaint by Valisure, a laboratory that tested the drug.
Despite the settlement, GSK maintains that there is no consistent evidence linking Zantac to an increased cancer risk.
GSK's shares rose by 5% following the announcement, as the settlement amount was lower than some analysts' estimates.